Intensive versus standard cholesterol lowering to slow coronary plaque in young and middle-aged adults with chronic coronary syndrome
Official title: Coronary Computed Tomography Study to Assess the Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome: A Nationwide, Multicentre, Randomized Controlled Trial
Run by Guangdong Provincial People's Hospital · NCT06896708 · Data updated 2026-11-12
This trial will test whether more intensive cholesterol lowering (LDL-C <1.0 mmol/L) compared with guideline-level lowering (LDL-C <1.8 mmol/L) can slow or reverse coronary plaque in adults 18–60 with chronic coronary syndrome and a 50–70% lesion on CCTA.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 766 (estimated) |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Locations | 7 sites (Chongqing, Chongqing Municipality and 6 other locations) |
| Status | Recruiting |
| Started | August 12, 2025 |
| Main results expected | July 1, 2027 |
| Study ends | March 1, 2028 |
| Registry record updated | December 17, 2025 |
| Trial ID | NCT06896708 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18–60 years old with chronic coronary syndrome managed without intervention, at least one CCTA-identified 50–70% coronary lesion, and baseline LDL-C levels meeting the trial's entry criteria (on statin with LDL-C ≥1.8 mmol/L or statin-naive with LDL-C ≥2.6 mmol/L).
✕Probably not a fit
Patients with left main or severe three-vessel disease, ultra-high-risk ASCVD, familial hypercholesterolemia, very high baseline LDL-C above the trial cutoffs, recent PCSK9/ezetimibe use, or those who do not meet the CCTA lesion criteria are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, open-label, randomized, parallel-group trial enrolling adults aged 18–60 with chronic coronary syndrome managed without revascularization and at least one 50–70% stenosis identified by coronary CT angiography (CCTA). Participants are randomized to an intensive lipid-lowering strategy targeting LDL-C <1.0 mmol/L and ≥50% reduction from baseline or to a guideline-directed strategy targeting LDL-C <1.8 mmol/L and ≥50% reduction. Coronary plaque volume and characteristics are quantified noninvasively by serial CCTA to compare plaque progression between groups. The trial examines whether deeper LDL-C reduction leads to greater plaque stabilization or regression in this younger patient population.
Why it matters
Potential benefit: If successful, more intensive LDL lowering could slow or reverse coronary plaque progression and may reduce future heart attack risk in younger adults with chronic coronary syndrome.
How similar studies have gone: Previous imaging and outcome studies have shown that lower LDL-C levels are associated with slower plaque progression and more regression, but randomized data specifically testing LDL-C targets below 1.0 mmol/L in young and middle-aged CCS patients are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has not been intervened and at least one leision with 50%-70% stenosis. 3\. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol/L or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-C≥2.6mmol/L. Exclusion Criteria: 1. Left main coronary artery disease or severe three-vessel disease; 2. Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors; 3. Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment; 4. The baseline LDL-C was relatively high (LDL-C≥2.6 mmol/L in those taking statins and ≥4.9 mmol/L in those not taking statins). 5. Familial hypercholesterolemia; 6. Known allergy/intolerance to lipid-lowering drugs used in the trial; 7. Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy; 8. Pregnant or breastfeeding female patients.
Where it's running
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China Recruiting -
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China Not yet recruiting -
The Ninth Clinical Medical College of Guangzhou University of Chinese Medicine
Dongguan, Guangdong, China Not yet recruiting -
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China Not yet recruiting -
The Eighth Affiliated Hospital of Sun Yat-sen University
Shenzhen, Guangdong, China Not yet recruiting -
Zhongshan People's Hospital
Zhongshan, Guangdong, China Not yet recruiting
Show 1 more location
-
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Common femoral vein-to-artery diameter ratio to detect elevated LVEDP
Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.
-
Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI
This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.
-
See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease
In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.
-
IVUS-Guided Left Main Stenting: IVUS-Guided vs Trained-Eye Approach
This trial tests whether using IVUS to guide left main bifurcation stenting is as good as using an angiography-driven, experience-based approach by an IVUS-savvy operator.
-
Can CZT-SPECT/CT quantify myocardial tracer uptake to match PET measurements in coronary artery disease?
This study tests whether CZT-SPECT/CT can quantify heart blood flow at rest and stress and see if the results align with PET measurements for people with coronary artery disease.
-
Ultrasound vs CT calcium scoring to reclassify symptomatic chest pain
This study tests whether carotid ultrasound can reclassify risk in adults with chest pain and suspected chronic coronary syndrome, compared with the CT calcium score.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.